Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 vs T-DM1 in HER2+ Advanced Breast Cancer
NCT04924699Phase 3Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MRG002 in breast cancer, sponsored by Hangzhou Miracogen. Status: unknown.
02
Drugs
MRG002
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04924699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924699.